丙戊酸钠联合左乙拉西坦应用于癫痫的临床研究

Clinical Study of Valproate Combined with Levetiracetam in Epilepsy

目的分析丙戊酸钠联合左乙拉西坦对癫痫的治疗效果,并探讨其应用价值。方法方便选取2017年6月-2019年3月期间该院接收的72例神经内科癫痫患者作为研究对象,根据随机法将其分成参照组与治疗组,参照组利用丙戊酸钠缓释片对患者施以治疗,治疗组利用丙戊酸钠缓释片联合左乙拉西坦片对患者施以治疗,分析并比较两组患者的临床治疗效果,并对比患者治疗后不良反应发生情况。结果经过对患者施以3个月的治疗,可知治疗组患者在临床治疗总有效率(94.4%),显著高于参照组(77.8%),差异有统计学意义(χ~2=4.425,P=0.078 <0.05);治疗组患者不良反应发生率为5.6%,明显低于参照组的25.0%,差异有统计学意义(χ~2=5.549,P=0.018 <0.05)。结论神经内科癫痫病临床表现较为复杂,其发病类型多,应用丙戊酸钠缓释片联合左乙拉西坦片方式对患者施以治疗,有利于提高临床疗效,值得研究推广。

Objective To analyze the effect of sodium valproate combined with levetiracetam in the treatment of epilepsy,and to explore its application value. Methods 72 patients with neurological epilepsy who were convenient admitted to the hospital from June 2017 to March 2019 were enrolled in the study. They were divided into a reference group and a treatment group according to the random method. The reference group was treated with sodium valproate sustained-release tablets. The patients were treated with treatment. The treatment group was treated with sodium valproate sustained-release tablets combined with levetiracetam tablets. The clinical effects of the two groups were analyzed and compared, and the adverse reactions after treatment were compared. Results After three months of treatment, the total effective rate of the treatment group(94.4%) was significantly higher than that of the reference group(77.8%). the difference was statistically significant(χ~2=4.425, P=0.078 <0.05);the incidence of adverse reactions in the study group was 5.6%, significantly lower than the 25.0% of the reference group, the difference was statistically significant(χ~2=5.549, P=0.018 <0.05). Conclusion The clinical manifestations of neurological epilepsy are more complicated, and there are many types of epidemics. The application of sodium valproate sustained-release tablets combined with levetiracetam in the treatment of patients is beneficial to improve clinical efficacy, which is worthy of research and promotion.